New drug shows multiple improvements for people with Parkinson's disease

Patients report positive changes across all measured areas of daily living

SEOUL, South Korea, Oct. 12, 2026 /PRNewswire/ -- After showing meaningful improvements in both the movement and daily lives of people with Parkinson's disease, and new drug will be submitted for regulatory approval.

Patients with Parkinson's, who can have difficulty moving, reported improvements in measures of daily living from the potential treatment, which also restored their 'good' movement time for an average of 36 more minutes a day than using their regular medication alone. Following these promising ARISE clinical trial results, which were presented at the International Congress of Parkinson's Disease and Movement Disorders, the drug, solengepras, will now be submitted to the Federal Drug Administration (FDA) in the United States for approval.

"It is especially encouraging that in addition to the improvements in the good 'on' time, the patients themselves felt overall benefits in their usual motor function," said Ron Postuma, Chair of the MDS International Congress Scientific Program Committee. "In fact, the self-reported improvements are higher than you might expect for a 36-minute on time difference, which shows there is still more to explore about the possibilities of this drug."

Solengepras works differently than other drugs currently on the market, so its progress could also open the door for further innovations using similar techniques.

Drooling and saliva was the most significant self-reported change, and other outcomes included improved daytime sleepiness.

About the 2026 MDS International Congress of Parkinson's Disease and Movement Disorders^®:
The MDS International Congress is the premier annual event to advance the clinical and scientific discipline of Movement Disorders, including Parkinson's disease. Convening thousands of leading clinicians, scientists and other health professionals from around the globe, the International Congress will introduce more than 2,000 scientific abstracts and provide a forum for education and collaboration on latest research and treatment findings.

About the International Parkinson and Movement Disorder Society:
The International Parkinson and Movement Disorder Society^® (MDS), an international society of more than 12,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. For more information about MDS, visit www.movementdisorders.org.

SOURCE International Parkinson and Movement Disorder Society